יתרות מזומנים למניה Seelos Therapeutics (SEEL)

סמל ולוגו של המותג seelostherapeutics.com (SEEL)

Seelos Therapeutics (SEEL) is investing in the development of intranasal peptides for emergency psychiatry, advancing precision medicine. The current cash per share reflects market dynamics, with the indicator valued at 0.00. The financial model relies on government procurement of depression therapies, while interest from specialized investors depends directly on the outcomes of clinical trials for CNS drugs.

SEEL Seelos Therapeutics, Inc: יתרות מזומנים למניה בטווח 04.07.2022 - 26.10.2024

פילוחים אנליטיים של חברת Seelos Therapeutics (SEEL)

- מחיר שוק ויעדי מחיר של אנליסטים:
- נתוני מזומנים ותזרימי מזומנים:
ניתוח מסכם של החברה:Seelos Therapeutics, Inc - SEEL
סחורת הדגל של Seelos Therapeutics Inc

Seelos Therapeutics focuses on completing mid-stage trials of inhaled ketamine. The cash per share trend reflects the business's intrinsic value, stripped of speculative noise and one-time payments. The current value of 0.00 on the cash per share chart allows for an assessment of the financial foundation's stability. Growth in this metric confirms liquidity, while stagnation signals inefficient capital management. For the investor, this metric is critical when assessing R&D risks.